VIDEO: 'Prostate cancer drug extended my life'
Early treatment with a chemotherapy drug, Docetaxel, extends the lives of patients with advanced prostate cancer by nearly two years, a major study shows. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - May 14, 2015 Category: Consumer Health News Source Type: news
Intermittent Docetaxel as First-line for Metastatic CRPCIntermittent Docetaxel as First-line for Metastatic CRPC
Does intermittent administration of docetaxel improve quality of life for patients with castration resistant prostate cancer? Future Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 5, 2015 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
CTCA at Western Regional Medical Center launches Phase II of PembroPlus clinical trial
(Cancer Treatment Centers of America) This innovative 'PembroPlus' clinical trial combines an immunotherapy drug (pembrolizumab) with already FDA-approved chemotherapy drugs (gemcitabine, docetaxel, nab-paclitaxel, vinorelbine, irinotecan, and/or liposomal doxorubicin). The addition of pembrolizumab is aimed at activating the body's own immune system to improve the results that otherwise might be achieved from chemotherapy alone. This combination of chemotherapy drugs is investigational in this study. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 28, 2015 Category: Cancer & Oncology Source Type: news
Bristol-Myers' Phase III lung cancer trial of Opdivo meets endpoint
Bristol-Myers Squibb has stopped CheckMate -057, an open-label, randomised Phase III trial, which is evaluating Opdivo (nivolumab) versus docetaxel in previously treated patients with advanced non-squamous non small cell lung cancer (NSCLC). (Source: Drug Development Technology)
Source: Drug Development Technology - April 19, 2015 Category: Pharmaceuticals Source Type: news
Ramucirumab Plus Docetaxel Improves Outcomes in Bladder CancerRamucirumab Plus Docetaxel Improves Outcomes in Bladder Cancer
Adding ramucirumab to docetaxel showed promising results as a second-line therapy in metastatic urothelial carcinoma. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 2, 2015 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
ADT Plus Docetaxel for Prostate Ca: Home Run or Foul Ball?
(MedPage Today) -- No survival benefit seen with androgen deprivation/chemotherapy combo. (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - February 28, 2015 Category: Endocrinology Source Type: news
HER2-Positive Metastatic Breast Cancer: New Standard of CareHER2-Positive Metastatic Breast Cancer: New Standard of Care
Combining two targeted agents, trastuzumab and pertuzumab, with docetaxel resulted in unprecedented survival in HER2-positive metastatic breast cancer. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 20, 2015 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Merrimack begins Phase II trial of MM-121 to treat patients with heregulin positive NSCLC
US-based Merrimack Pharmaceuticals has started a Phase II clinical trial of its fully human monoclonal antibody, MM-121, in combination with docetaxel or pemetrexed versus docetaxel or pemetrexed alone to treat patients with heregulin positive, local… (Source: Drug Development Technology)
Source: Drug Development Technology - February 20, 2015 Category: Pharmaceuticals Source Type: news
January's top stories: Bristol-Myers stops Opdivo trial, Boehringer COPD study
Bristol-Myers Squibb (BMS) stopped its open-label, randomised Phase III trial (CheckMate -017) evaluating Opdivo versus docetaxel, Boehringer started patient enrolment in its Dynagito study to treat COPD, while Medivation and Astellas report positive… (Source: Drug Development Technology)
Source: Drug Development Technology - February 3, 2015 Category: Pharmaceuticals Source Type: news
Bristol-Myers says panel finds Opdivo lung cancer study meets endpoint
(Reuters) - Bristol-Myers Squibb Co said the independent data monitoring committee concluded that a late stage study evaluating Opdivo versus docetaxel in previously treated patients with advanced, squamous cell non-small cell lung cancer met its endpoint. (Source: Reuters: Health)
Source: Reuters: Health - January 12, 2015 Category: Consumer Health News Tags: healthNews Source Type: news
Bristol-Myers' Phase III lung cancer trial of Opdivo stopped early
Bristol-Myers Squibb (BMS) has stopped its open-label, randomised Phase III trial (CheckMate -017) evaluating Opdivo versus docetaxel in previously treated patients with advanced, squamous cell non-small cell lung cancer (NSCLC). (Source: Drug Development Technology)
Source: Drug Development Technology - January 12, 2015 Category: Pharmaceuticals Source Type: news
FDA approves drug that extends survival in the most common type of lung cancer
UCLA
Dr. Edward Garon
The Food and Drug Administration today approved a new drug to treat non-small-cell lung cancer (NSCLC), offering people new hope in fighting the disease. Lung cancer is expected to lead to more than 150,000 deaths in the United States this year alone, and NSCLC accounts for about 85 percent of all lung cancers.
The drug, Cyramza (ramucirumab), was tested on more than 1,200 people with NSCLC whose cancer worsened during or after first-line chemotherapy. The research was conducted as part of a multi-year, Phase 3 clinical trial at UCLA and other centers in 26 countries on six continents. This is the fi...
Source: UCLA Newsroom: Health Sciences - December 13, 2014 Category: Universities & Medical Training Source Type: news
New Drug Ofev Gaining Momentum in Fight Against Mesothelioma
Mesothelioma patients battling shortness of breath — a symptom that makes everyday activities increasingly difficult — may soon find relief with nintedanib, a new anti-cancer drug shown to relieve respiratory distress.
Nintedanib recently received approval from the U.S. Food and Drug Administration (FDA) for the treatment of idiopathic pulmonary fibrosis (IPF), a lung scarring condition with similarities to asbestosis.
German-based drugmaker Boehringer Ingelheim markets the drug under the brand name Ofev. The European Commission also granted the marketing of the drug as Vargatef for use with docetaxel to combat lung ca...
Source: Asbestos and Mesothelioma News - December 8, 2014 Category: Environmental Health Authors: Tim Povtak Tags: Research & Clinical Trials Source Type: news
Dr Reddy's Laboratories launches Docetaxel injection in US
Docetaxel injection USP 20 mg/mL and 80 mg/4 mL are available as a single dose, one vial formulation that does not require a prior dilution. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 24, 2014 Category: Pharmaceuticals Source Type: news
Sequencing Radium-223 and Docetaxel in Prostate CancerSequencing Radium-223 and Docetaxel in Prostate Cancer
A prespecified analysis of the ALSYMPCA data suggests radium-223 can be used in sequence with docetaxel in metastatic castration-resistant prostate cancer. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 24, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
